Excitingly, regardless of histological grading, our new molecular classification model on the basis of IDH1/2 mutational status and ATRX/Ki-67 expression could exactly reflect the biological properties of the three subgroups of astrocytic tumors with distinct clinical prognosis. This evidence concerns the gene MKI67 and astrocytic tumor.